Future role of micafungin in the treatment of invasive mycoses caused by filamentous fungi (Q44790540)

6 December 2017

1 reference

title

Future role of micafungin in the treatment of invasive mycoses caused by filamentous fungi (English)

1 reference

6 December 2017

1 reference

Miguel Salavert-Lletí

series ordinal

1

1 reference

6 December 2017

Rafael Zaragoza-Crespo

series ordinal

2

1 reference

6 December 2017

publication date

1 March 2009

1 reference

Revista iberoamericana de micologia

6 December 2017

published in

1 reference

6 December 2017

volume

26

1 reference

6 December 2017

issue

1

1 reference

6 December 2017

page(s)

81-89

1 reference

Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease: an emerging fungal pathogen.

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Breakthrough trichosporonosis in patients with acute myeloid leukemia receiving micafungin

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Antifungal agents in neonates: issues and recommendations.

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Micafungin in pediatrics: when one size does not fit all

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Immunocompromised hosts: immunopharmacology of modern antifungals.

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Disseminated mucormycosis associated with invasive pulmonary aspergillosis in a patient treated for post-transplant high-grade non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Chronic obstructive pulmonary disease patients with invasive pulmonary aspergillosis: benefits of intensive care?

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Combined action of micafungin, a new echinocandin, and human phagocytes for antifungal activity against Aspergillus fumigatus

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Micafungin: a review of its use in adults for the treatment of invasive and oesophageal candidiasis, and as prophylaxis against Candida infections

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on Antimicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease.

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Disseminated aspergillosis in intensive care unit patients: an autopsy study

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Post mortem examination in the intensive care unit: still useful?

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Salvage therapy for invasive aspergillosis.

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Aspergillus endocarditis after cardiac surgery

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Comparison of echinocandin antifungals

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Micafungin for the prophylaxis and treatment of Candida infections

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Two cases of pulmonary aspergillosis successfully treated with combinated micafungin and itraconazole therapy

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Breakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Synergistic effect of posaconazole and caspofungin against clinical zygomycetes

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Comparison of micafungin and fluconazole for experimental Candida keratitis in rabbits

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Pharmacokinetics of Antifungal Agent Micafungin in Critically Ill Patients Receiving Continuous Hemodialysis Filtration

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure.

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Combination echinocandin-polyene treatment of murine mucormycosis

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Antifungal activity of micafungin against Candida and Aspergillus spp. isolated from pediatric patients in Japan

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Clinical efficacy of micafungin for chronic pulmonary aspergillosis

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Outcome of ICU treatment in invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Zygomycosis: an emerging fungal infection with new options for management

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Isolation of Aspergillus in critically ill patients: a potential marker of poor outcome

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Invasive aspergillosis in the intensive care unit

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Galactomannan in Bronchoalveolar Lavage Fluid

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Invasive aspergillosis in the ICU: an emerging disease

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Invasive aspergillosis in critically ill patients without malignancy

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Comparison of caspofungin and amphotericin B for invasive candidiasis

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

[Successful treatment of invasive sinus aspergillosis with micafungin and itraconazole]

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

A case of invasive central nervous system aspergillosis treated with micafungin with monitoring of micafungin concentrations in the cerebrospinal fluid.

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Successful micafungin (FK463) treatment of invasive pulmonary aspergillosis in a patient with acute lymphoblastic leukemia in a phase II study

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Successful treatment of refractory chronic necrotizing pulmonary aspergillosis with micafungin

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Micafungin activity against Candida bloodstream isolates: effect of growth medium and susceptibility testing method

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Post-operative aspergillosis

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Pediatric antifungal utilization: new drugs, new trends

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Invasive Pulmonary Aspergillosis in Patients with Chronic Obstructive Pulmonary Disease: Report of Eight Cases and Review

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Treatment of zygomycosis: current and new options

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

In vitro interactions of itraconazole and micafungin against clinically important filamentous fungi

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Efficacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspofungin breakthrough pulmonary zygomycosis

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

In vitro interactions of micafungin with other antifungal drugs against clinical isolates of four species of Cryptococcus.

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

In vitro interaction of micafungin with conventional and new antifungals against clinical isolates of Trichosporon, Sporobolomyces and Rhodotorula

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

In vitro susceptibility of 15 strains of zygomycetes to nine antifungal agents as determined by the NCCLS M38-A microdilution method

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Novel perspectives on mucormycosis: pathophysiology, presentation, and management

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

A case of successful resection after long-term medical treatment of invasive pulmonary aspergillosis following living donor liver transplantation

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Efficacy and safety of micafungin in febrile neutropenic patients treated for hematological malignancies.

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Invasive aspergillosis in critically ill patients: analysis of risk factors for acquisition and mortality

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Invasive aspergillosis in critically ill patients: attributable mortality and excesses in length of ICU stay and ventilator dependence

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Clinical relevance of Aspergillus isolation from respiratory tract samples in critically ill patients

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Editorial commentary: what is the role of combination therapy in management of zygomycosis?

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Killing activity of micafungin against Aspergillus fumigatus hyphae assessed by specific fluorescent staining for cell viability

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

Micafungin, a novel antifungal agent, as empirical therapy in acute leukemia patients with febrile neutropenia.

1 reference

https://api.crossref.org/works/10.1016/S1130-1406(09)70015-4

7 January 2021

10.1016/S1130-1406(09)70015-4

Identifiers

DOI

1 reference

6 December 2017

1 reference